154 related articles for article (PubMed ID: 37676349)
1. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality.
Madsen K; Lee K; Chen S; Chen C; Law AD; Gerbitz A; Kumar R; Kim D; Lam W; Pasic I; Viswabandya A; Michelis FV; Nampoothiri RV; Lipton JH; Novitzky-Basso I; Mattsson J
Support Care Cancer; 2023 Sep; 31(10):564. PubMed ID: 37676349
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
Zhou W; Chen G; Gong D; Gao Y; Yu L
Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
[TBL] [Abstract][Full Text] [Related]
3. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
4. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
5. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
6. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.
Kaito S; Kurosawa S; Najima Y; Sakaida E; Shingai N; Fukuda T; Tachibana T; Uchida N; Ozawa Y; Sawa M; Nakazawa H; Ota S; Kato J; Nakamae H; Katayama Y; Eto T; Tanaka J; Kanda Y; Atsuta Y; Arai Y; Kako S;
Transplant Cell Ther; 2022 Jun; 28(6):326.e1-326.e10. PubMed ID: 35306218
[TBL] [Abstract][Full Text] [Related]
8. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
Wei H; Kuang P; Liu T
Ann Hematol; 2020 Nov; 99(11):2619-2628. PubMed ID: 32960314
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
11. Risk factors associated with liver injury and impact of liver injury on transplantation-related mortality in pediatric recipients of allogeneic hematopoietic stem cell transplantation.
Radhakrishnan K; Bishop J; Jin Z; Kothari K; Bhatia M; George D; Garvin JH; Martinez M; Ovchinsky N; Lobritto S; Elsayed Y; Satwani P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):912-7. PubMed ID: 23467127
[TBL] [Abstract][Full Text] [Related]
12. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
14. Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation.
Kaito S; Wada A; Adachi H; Konuma R; Kishida Y; Nagata A; Konishi T; Yamada Y; Kumagai T; Yoshifuji K; Mukae J; Akiyama M; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Ohashi K; Sakamaki H; Doki N
Ann Hematol; 2020 Jul; 99(7):1655-1665. PubMed ID: 32524200
[TBL] [Abstract][Full Text] [Related]
15. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting.
Jaime-Pérez JC; Picón-Galindo E; Herrera-Garza JL; Gómez-Almaguer D
Hematol Oncol; 2021 Feb; 39(1):87-96. PubMed ID: 32978807
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.
Forcina A; Lorentino F; Marasco V; Oltolini C; Marcatti M; Greco R; Lupo-Stanghellini MT; Carrabba M; Bernardi M; Peccatori J; Corti C; Ciceri F
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1476-1482. PubMed ID: 29501780
[TBL] [Abstract][Full Text] [Related]
19. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
[TBL] [Abstract][Full Text] [Related]
20. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
